OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 42.33%10.16B | 42.62%6.84B | 46.23%4.19B | 51.34%1.99B | 26.59%7.14B | 19.67%4.8B | 15.39%2.87B | 9.63%1.32B | 25.61%5.64B | 28.03%4.01B |
Operating revenue | 42.33%10.16B | 42.62%6.84B | 46.23%4.19B | 51.34%1.99B | 26.59%7.14B | 19.67%4.8B | 15.39%2.87B | 9.63%1.32B | 25.61%5.64B | 28.03%4.01B |
Other operating revenue | 67.83%59.66M | ---- | 94.89%23.86M | ---- | -10.52%35.55M | ---- | -30.18%12.24M | ---- | -10.08%39.73M | ---- |
Total operating cost | 41.41%9.37B | 40.51%6.32B | 43.86%3.89B | 47.63%1.85B | 25.61%6.62B | 19.54%4.5B | 15.20%2.7B | 10.09%1.26B | 24.41%5.27B | 27.24%3.77B |
Operating cost | 43.98%8.06B | 43.70%5.37B | 47.10%3.28B | 52.82%1.56B | 27.40%5.6B | 19.47%3.74B | 14.33%2.23B | 9.15%1.02B | 24.76%4.39B | 27.59%3.13B |
Operating tax surcharges | 28.72%46.39M | 25.26%31.26M | 40.79%20.83M | 91.05%11.57M | 46.51%36.04M | 35.67%24.96M | 35.03%14.79M | 1.36%6.06M | 45.21%24.6M | 69.40%18.39M |
Operating expense | 19.94%261.22M | 28.07%224.13M | 41.83%144.64M | 21.42%66.44M | -4.44%217.79M | 9.15%175M | 3.29%101.98M | 9.69%54.72M | 24.94%227.92M | 19.30%160.34M |
Administration expense | 22.49%208.63M | 16.35%147.45M | 8.57%89.01M | 8.38%46.02M | 2.22%170.33M | 3.46%126.73M | 1.63%81.99M | 1.13%42.46M | 3.54%166.63M | 7.72%122.49M |
Financial expense | 2,252.62%29.89M | 1,591.72%19.03M | 967.47%14.29M | 218.27%8.65M | 83.97%-1.39M | 126.17%1.13M | 11.18%-1.65M | 77.23%2.72M | -179.62%-8.66M | -194.71%-4.3M |
-Interest expense (Financial expense) | 25.51%31.66M | 42.70%25.29M | 40.55%18.07M | 83.87%10.27M | 70.33%25.23M | 128.08%17.72M | 132.45%12.85M | 111.91%5.59M | 102.51%14.81M | 69.83%7.77M |
-Interest Income (Financial expense) | 34.91%-12.41M | 12.50%-10.89M | -31.43%-8.77M | -57.67%-5.6M | -46.22%-19.06M | -15.20%-12.45M | 13.31%-6.67M | -8.80%-3.55M | -80.55%-13.03M | -96.57%-10.8M |
Research and development | 26.19%764.25M | 21.99%531.32M | 23.03%339.09M | 24.86%160.35M | 28.63%605.63M | 28.16%435.56M | 33.04%275.62M | 21.79%128.42M | 35.53%470.85M | 39.47%339.85M |
Credit Impairment Loss | -24.88%-89.06M | -57.47%-43.61M | -167.16%-13.47M | -14.18%5.88M | -56.44%-71.32M | -99.47%-27.69M | -302.49%-5.04M | 64.30%6.85M | -282.66%-45.59M | -507.32%-13.88M |
Asset Impairment Loss | -131.70%-96.83M | -78.43%-41.96M | -87.18%-27.67M | -169.86%-11.48M | -117.74%-41.79M | -80.32%-23.52M | -35.50%-14.78M | 19.09%-4.25M | 27.03%-19.19M | 35.43%-13.04M |
Other net revenue | -125.16%-89.24M | -19.97%-20.56M | -159.85%-1.82M | 6.17%12.93M | -293.93%-39.63M | -294.83%-17.14M | -81.14%3.04M | 88.71%12.18M | -141.07%-10.06M | -71.39%8.8M |
Fair value change income | 2,008.79%4.75M | 1,753.26%3.5M | --1.93M | --942.99K | 115.47%225.44K | 113.84%189.08K | --0 | ---- | -537.75%-1.46M | -1,937.54%-1.37M |
Invest income | 44.69%27.06M | 77.81%21.17M | 106.36%15.03M | 89.37%6.85M | -27.85%18.7M | -10.64%11.9M | -22.48%7.28M | 21.69%3.62M | -45.67%25.92M | -64.53%13.32M |
-Including: Investment income associates | 48.21%22.9M | 50.21%17.88M | 66.80%12.15M | 46.70%5.31M | -32.36%15.45M | 6.78%11.9M | -1.67%7.28M | 25.92%3.62M | 14.18%22.84M | -29.21%11.15M |
Asset deal income | -63.08%-914.84K | -50.19%-790.9K | -122.66%-976.44K | 102.92%12.24K | -18.42%-560.98K | -80.88%-526.6K | -591.15%-438.53K | -3,300.22%-418.91K | 88.15%-473.74K | 92.23%-291.12K |
Other revenue | 19.32%65.75M | 82.74%41.14M | 45.69%23.33M | 68.02%10.73M | 79.35%55.11M | -6.43%22.51M | -6.46%16.01M | 1.54%6.39M | 59.85%30.73M | 76.29%24.06M |
Operating profit | 48.25%701.94M | 77.99%496.52M | 80.68%302.92M | 108.87%149.2M | 33.51%473.47M | 10.70%278.95M | 8.20%167.66M | 9.33%71.43M | 29.43%354.63M | 24.50%252M |
Add:Non operating Income | 101.44%6.04M | -17.00%2.26M | -37.95%1.08M | -27.65%19.8K | 70.34%3M | 170.31%2.72M | 164.37%1.73M | -75.76%27.37K | 62.98%1.76M | 196.80%1.01M |
Less:Non operating expense | 172.31%8.65M | 103.13%4.44M | 141.93%2.24M | 207.36%492.62K | -12.76%3.18M | 56.72%2.19M | -14.52%925.72K | -63.89%160.28K | -27.78%3.64M | -29.61%1.39M |
Total profit | 47.76%699.33M | 76.87%494.33M | 79.12%301.76M | 108.60%148.73M | 34.17%473.29M | 11.08%279.48M | 9.02%168.47M | 9.68%71.3M | 30.63%352.75M | 25.32%251.61M |
Less:Income tax cost | 1,097.39%42.63M | 217.78%25.54M | 178.95%12.31M | 173.67%5.36M | 111.19%3.56M | -19.18%-21.68M | -58.08%-15.6M | -50.20%-7.28M | -15.31%-31.83M | -189.33%-18.19M |
Net profit | 39.80%656.7M | 55.66%468.79M | 57.25%289.44M | 82.44%143.37M | 22.14%469.73M | 11.62%301.17M | 11.97%184.06M | 12.49%78.58M | 29.21%384.57M | 30.31%269.8M |
Net profit from continuing operation | 39.80%656.7M | 55.66%468.79M | 57.25%289.44M | 82.44%143.37M | 22.14%469.73M | 11.62%301.17M | 11.97%184.06M | 12.49%78.58M | 29.21%384.57M | 30.31%269.8M |
Less:Minority Profit | 8.46%5.33M | 11.99%4.11M | 7.50%2.52M | 3.10%1.08M | 19.52%4.91M | 35.08%3.67M | 44.30%2.34M | 51.80%1.05M | 516.00%4.11M | 336.20%2.72M |
Net profit of parent company owners | 40.13%651.36M | 56.20%464.68M | 57.89%286.93M | 83.52%142.28M | 22.17%464.82M | 11.39%297.49M | 11.64%181.72M | 12.10%77.53M | 27.40%380.46M | 28.28%267.08M |
Earning per share | ||||||||||
Basic earning per share | 31.91%1.24 | 43.55%0.89 | 44.74%0.55 | 68.75%0.27 | 17.50%0.94 | 10.71%0.62 | 11.76%0.38 | 6.67%0.16 | 29.03%0.8 | 27.27%0.56 |
Diluted earning per share | 31.91%1.24 | 44.26%0.88 | 58.82%0.54 | 68.75%0.27 | 18.99%0.94 | 8.93%0.61 | 0.00%0.34 | 14.29%0.16 | 29.51%0.79 | 27.27%0.56 |
Other composite income | -90.79%86.68K | -258.06%-2.02M | -115.63%-467K | 40.13%-2.73M | -91.92%941.05K | -90.17%1.28M | -56.45%2.99M | -105.86%-4.56M | 233.68%11.65M | 111.40%12.99M |
Other composite income of parent company owners | -94.60%50.23K | -260.69%-2.01M | -116.26%-479.79K | 39.76%-2.73M | -91.93%929.91K | -90.25%1.25M | -56.58%2.95M | -105.65%-4.53M | 226.95%11.52M | 108.49%12.83M |
Other composite income of minority owners | 227.31%36.45K | -133.01%-8.69K | -65.51%12.79K | 98.94%-302.64 | -91.63%11.14K | -83.32%26.32K | -42.87%37.09K | -147.19%-28.59K | 526.33%133.07K | 1,635.98%157.77K |
Total composite income | 39.54%656.78M | 54.33%466.78M | 54.49%288.98M | 89.99%140.64M | 18.79%470.67M | 6.95%302.44M | 9.23%187.05M | 9.43%74.02M | 31.58%396.22M | 32.64%282.79M |
Total composite income of parent company owners | 39.86%651.42M | 54.87%462.67M | 55.11%286.45M | 91.16%139.56M | 18.82%465.75M | 6.73%298.74M | 8.91%184.67M | 9.02%73M | 29.73%391.98M | 30.58%279.91M |
Total composite income of minority owners | 8.95%5.37M | 10.96%4.11M | 6.36%2.53M | 5.95%1.08M | 16.03%4.93M | 28.58%3.7M | 40.95%2.38M | 50.17%1.02M | 516.31%4.25M | 347.70%2.88M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.